Sign In
Buy EDSA
$5.11
-0.140 (-2.67%)
At Close: Jul 31, 2026
EDSA: Licenses Two Potential COVID-19 Treatments…
12:35pm, Friday, 24'th Apr 2020
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Licenses Two Assets for Potentially Treating COVID-19 On April 20, 2020, Edesa Biotech, Inc. (NASDAQ:EDSA) announced
6 Stocks Moving In Thursday's After Hours Session
09:11pm, Thursday, 23'rd Apr 2020
Gainers
World Wrestling Entertainment (NYSE: WWE) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.
Edwards Lifesciences (NYSE:...
Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
01:00pm, Monday, 20'th Apr 2020
TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImm
Contrasting Edesa Biotech (NASDAQ:EDSA) & Stemline Therapeutics (NASDAQ:STML)
05:32am, Wednesday, 08'th Apr 2020
Edesa Biotech (NASDAQ:EDSA) and Stemline Therapeutics (NASDAQ:STML) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of
EDSA: Initiating Coverage of Edesa Biotech, Inc.; Dermatology and GI Focused Drug Development…
02:33pm, Thursday, 02'nd Apr 2020
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT We are initiating coverage of Edesa Biotech, Inc. (NASDAQ:EDSA) with a valuation of $5.00. Edesa is a biopharmaceutical company focus
Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada
11:30am, Thursday, 12'th Mar 2020
TORONTO, ON / ACCESSWIRE / March 12, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
12:28pm, Friday, 28'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLa
Edesa Biotech Reports Fiscal 1st Quarter 2020 Results
09:10pm, Thursday, 13'th Feb 2020
TORONTO, ON / ACCESSWIRE / February 13, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three months ended December 31, 2
Daily Insider Ratings Round Up 1/10/20
12:25am, Wednesday, 15'th Jan 2020
Tables of the top insider purchases and sales filed with the SEC on 1/10/20, based on dollar value. Dollar values often do not equate with significance when it
Edesa Biotech Announces $4.36 million Registered Direct Offering
02:21pm, Monday, 06'th Jan 2020
TORONTO, ON / ACCESSWIRE / January 6, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive securities purchase agreements
Edesa Biotech Reports Financial Results for Short Period Fiscal Year
09:30pm, Thursday, 12'th Dec 2019
TORONTO, ON / ACCESSWIRE / December 12, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the nine-month period ended September
Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions
12:30pm, Tuesday, 03'rd Dec 2019
TORONTO, ON / ACCESSWIRE / December 3, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported that the company's lead product candidate, EB01, has demonst
Edesa Biotech Announces Upcoming Conference Schedule
12:30pm, Tuesday, 05'th Nov 2019
TORONTO, ON / ACCESSWIRE / November 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that its management will present at the H.C. Wainwright 5th
Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study
11:30am, Monday, 21'st Oct 2019
TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clin
Edesa Biotech to Present at H. C. Wainwright Global Investment Conference
12:30pm, Thursday, 29'th Aug 2019
TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present
